Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), represents one of the most clinically challenging subtypes of breast cancer1. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.